EICHORCondition: ADHD · Attention Deficit Hyperactivity Disorder · ADHD - Combined Type · Sponsor: Cingulate Therapeutics
A Phase 3, randomized, double-blind, placebo-controlled, multi-center, fixed-dose, parallel-group efficacy and safety study in a pediatric population (6-17) with Attention-Deficit/Hyperactivity Disorder (ADHD) using CTx-1301 (d-MPH). The study will be comprised of a screening period, a double-blind randomized phase, and a safety follow-up visit.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Clinical Neuroscience Solutions, Inc. | Jacksonville, Florida, United States | — |
| Meridien Research | Maitland, Florida, United States | — |
| Clinical Neuroscience Solutions, Inc. | Orlando, Florida, United States | — |
| Atlanta Center for Medical Research | Atlanta, Georgia, United States | — |
| Sisu Bhr, Llc | Springfield, Massachusetts, United States | — |
| Neurobehavioral Medicine Group | Bloomfield Hills, Michigan, United States | — |
| St Charles Psychiatric Associates & Midwest Research Group | Saint Charles, Missouri, United States | — |
| Center for Psychiatry and Behavioral Medicine. Inc. | Las Vegas, Nevada, United States | — |
| Hassman Research Institute | Berlin, New Jersey, United States | — |
| Icahn School of Medicine at Mount Sinai | New York, New York, United States | — |
| Dayton Clinical Research | Dayton, Ohio, United States | — |
| SP Research PLLC | Oklahoma City, Oklahoma, United States | — |
+ 12 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05286762